Core Viewpoint - The fourth batch of encouraged generic drug catalog includes 21 varieties and 47 specifications, focusing on patient treatment needs and addressing weak R&D areas in domestic companies [1][2]. Group 1: Drug Catalog and Patient Needs - The new catalog includes drugs for oncology, nervous system, assisted reproduction, and radioactive diagnosis, prioritizing products with new targets and mechanisms [1]. - The inclusion of low-adverse reaction assisted reproductive drugs aligns with the promotion of fertility policies, providing significant support for families wishing to have children [2]. - The catalog also features domestically practiced products, such as deflazacort for treating rare diseases, which can alleviate urgent patient needs [2]. Group 2: Policy Implementation and Industry Development - Effective accessibility to generic drugs relies on the implementation of supportive policies, with the National Health Commission establishing a communication mechanism to promote R&D, registration, production, and reimbursement [3]. - The selection of drugs in the fourth batch reflects a comprehensive consideration of patient needs, aiming to provide high-quality and effective options for both common and rare diseases [3]. - This approach not only demonstrates a commitment to patient welfare but also indicates a direction for the sustainable development of the generic drug industry, addressing the challenges of medication accessibility [3].

Core Viewpoint - The National Health Commission of China, in collaboration with various governmental departments, has released the "Fourth Batch of Encouraged Generic Drug List" to enhance drug supply security and address clinical shortages in the market [1]. Group 1: Drug Selection Criteria - The list includes 21 drug varieties and 47 specifications, focusing on patient treatment needs and addressing gaps in the market [2]. - Priority is given to products with new targets and mechanisms, such as difelikefalin for chronic kidney disease-related itching [2]. - The list also includes drugs recommended in international guidelines, like suvorexant for insomnia, to provide more treatment options [2]. - Products with lower adverse reactions, such as progesterone formulations for assisted reproduction, are prioritized to support fertility policies [2]. - The selection considers accessibility, including products already practiced clinically in China, like deflazacort for Duchenne muscular dystrophy [2]. Group 2: Drug List Details - The list features various drugs, including: - Bexarotene (topical gel, 1%) [3] - Deflazacort (tablets in multiple dosages) [3] - Difelikefalin (injection, 65mcg/1.3mL) [3] - Suvorexant (tablets in multiple dosages) [4] - Progesterone (vaginal gel and suppository) [5] - Additional drugs include midostaurin, opicapone, and others, with various formulations and dosages [4][5][6].

Core Viewpoint - The fourth batch of encouraged generic drug catalog includes 21 varieties and 47 specifications, focusing on patient treatment needs and addressing weak R&D areas in domestic companies [1] Group 1: Drug Categories - The catalog includes drugs for oncology, nervous system, assisted reproduction, and radioactive diagnosis [1] - New target and mechanism products are prioritized, such as a drug for alleviating moderate to severe itching in chronic kidney disease patients undergoing dialysis [1] Group 2: Drug Effectiveness and Recommendations - Products already recommended in first-line guidelines abroad are prioritized, like Suvorexant for treating insomnia, which addresses difficulties in falling asleep and reduces daytime drowsiness and fatigue [1] - The catalog also emphasizes low adverse reaction iterative products, such as progesterone vaginal sustained-release gel and suppositories for assisted reproduction, which mitigate injection-related side effects [1] Group 3: Accessibility and Clinical Practice - The selection process considers drug accessibility and prioritizes products with existing clinical practices in China, such as Deflazacort for treating Duchenne muscular dystrophy [1]

Core Viewpoint - The fourth batch of encouraged generic drug catalog was released, including 21 drug varieties and 47 specifications, addressing the issue of drug shortages in China and aiming to enhance domestic drug development and production capabilities [1][2]. Group 1: Drug Catalog Expansion - The fourth batch of the catalog is an update after two years, bringing the total number of encouraged generic drug varieties to 110, following three previous batches released in 2019, 2021, and 2023, which included 89 drugs [1]. - The new catalog continues to focus on major diseases such as cancer and rare diseases, while also addressing shortages in treatments for chronic diseases, mental health, and assisted reproduction, reflecting the changing disease burden and clinical needs due to demographic trends [1][2]. Group 2: Selection Criteria and Focus Areas - The selection of drugs for the fourth batch was guided by patient treatment needs, considering clinical guidelines and domestic research status, with input from experts across various fields [2]. - New entries include drugs targeting new mechanisms and indications, such as a treatment for severe itching in chronic kidney disease patients undergoing dialysis and four radioactive drugs not yet marketed domestically [2]. Group 3: Specific Drug Examples - The inclusion of Suvorexant, a drug for insomnia, aims to address the high prevalence of insomnia symptoms among the Chinese population, with 59% of surveyed residents reporting such issues [3]. - The catalog also includes a vaginal sustained-release gel of progesterone for assisted reproduction, which aims to alleviate adverse reactions from traditional injection methods, although it faces regulatory challenges in the domestic market [4]. Group 4: Challenges in Generic Drug Development - Despite being a major player in generic drugs, China faces challenges in becoming a "strong country" in this sector, including technical barriers and insufficient incentives for research and development [5]. - As of September last year, only 40 out of 89 drugs from the previous three catalogs had been approved for market, indicating that many drugs remain unavailable for domestic generic production [5]. Group 5: Future Support and Policy Directions - The government aims to enhance the enthusiasm for generic drug development through policies that provide market exclusivity for certain categories of drugs, including those for rare diseases and children's medications [6]. - Future efforts will focus on supporting clinical trials, key technology research, and expedited review processes for drugs listed in the encouraged generic drug catalog [6].

Core Viewpoint - The fourth batch of encouraged generic drug catalog has been released, including 21 drug varieties and 47 specifications, addressing the shortage of clinical supplies and the need for domestic drug development [1][2]. Group 1: Drug Catalog Expansion - The fourth batch of the encouraged generic drug catalog includes 21 drug varieties, bringing the total to 110 since the first three batches were released in 2019, 2021, and 2023 [1]. - The new catalog focuses on major diseases such as cancer and rare diseases, as well as chronic diseases, mental health issues, and reproductive health, reflecting the changing disease burden and clinical needs due to demographic trends [1][2]. Group 2: Selection Criteria and Clinical Needs - The selection of drugs for the fourth batch was guided by patient treatment needs, considering clinical guidelines and domestic research status, with input from various experts [2]. - New drugs with novel targets and mechanisms, such as those for chronic kidney disease-related itching, have been included, along with radioactive drugs not yet available in the domestic market [2]. Group 3: Specific Drug Examples - Suvorexant, a new drug for insomnia, has been included in the catalog to address the high prevalence of insomnia symptoms among the Chinese population, with 59% of surveyed residents reporting such issues [3]. - The catalog also includes drugs for rare diseases, such as Deflazacort for Duchenne muscular dystrophy, and aims to enhance reproductive health with low-adverse-effect products [3][4]. Group 4: Challenges in Generic Drug Development - Despite being a major player in generic drugs, China faces challenges in becoming a stronghold in this sector due to technical barriers and insufficient incentives for research and development [5][6]. - As of September last year, only 40 out of 89 drugs listed in the previous three catalogs had been approved for market entry, indicating a significant gap in the availability of generic drugs [5]. Group 5: Future Support and Policy Directions - The government aims to enhance support for the encouraged generic drug catalog through improved clinical trials, key technology research, and expedited review processes [6]. - Policies are being developed to provide market exclusivity for certain categories of drugs, including those for rare diseases and children's medications, to stimulate research and development [6].

Group 1 - The article lists various pharmaceutical products along with their names, formulations, and types, indicating a focus on drug development and market offerings [2][3][4][5][6][7][8][9]. - Specific drugs mentioned include bexarotene, deflazacort, difelikefalin, eluxadoline, and others, highlighting a diverse range of therapeutic areas [2][4][5][7]. - The formulations include capsules, tablets, injectable forms, and gels, suggesting a comprehensive approach to drug delivery methods [2][3][4][5][6][7][8][9]. Group 2 - The document provides detailed information on the dosage forms and types of each drug, which is crucial for understanding their application in clinical settings [2][3][4][5][6][7][8][9]. - The presence of both oral and injectable formulations indicates a strategic focus on meeting various patient needs and preferences [2][4][5][7][8][9]. - The inclusion of specific dosage amounts and types, such as micrograms and milligrams, reflects the precision required in pharmaceutical development [2][4][5][6][7][8][9].

Core Insights - The National Health Commission of China, in collaboration with various governmental departments, has developed the "Fourth Batch of Encouraged Generic Drug List," which includes 21 varieties and 47 specifications of drugs aimed at addressing clinical supply shortages and patent expirations [1][2] Group 1: Drug Selection Criteria - The selection of drugs is based on clinical needs and disease burden, focusing on enhancing treatment adherence and ensuring the feasibility of research and production [1] - The list prioritizes products with new targets and mechanisms, particularly those addressing weak areas in domestic research, such as a drug for alleviating moderate to severe itching in chronic kidney disease patients undergoing dialysis [1] - It includes four radioactive drugs that have not yet been marketed domestically, covering therapeutic, diagnostic, and localization uses [1] Group 2: Inclusion of Effective Products - The list favors drugs that have been recommended in international first-line guidelines, such as Suvorexant for treating insomnia, which addresses difficulties in falling asleep and reduces daytime drowsiness and fatigue [1] - This inclusion aims to provide more options for clinical use in response to the inadequacy of currently available medications in China [1] Group 3: Focus on Reproductive Health - The list also emphasizes low-adverse reaction iterative products to support fertility policies, such as progesterone vaginal sustained-release gel and suppositories, which mitigate adverse reactions from long-term high-dose injections during assisted reproductive technology [1] - The selection considers the accessibility of medications, prioritizing products already in clinical practice domestically, such as Deflazacort for treating Duchenne muscular dystrophy [2]

Core Insights - Duchenne Muscular Dystrophy (DMD) affects approximately 70,000 patients in China, with a prevalence of 1 in every 5,000 newborn boys [1][2] - The standard treatment with corticosteroids can extend median survival by over 10 years, yet only 23% of patients in China receive this treatment [1][6] - The approval of Vamorolone, the first innovative corticosteroid for DMD in China, marks a significant advancement in treatment options [1][7] Patient Statistics - DMD is a genetic disorder caused by mutations in the DMD gene, leading to progressive muscle degeneration and associated complications [2] - Globally, there are about 250,000 DMD patients, with China having one of the highest numbers [2] - Approximately 30% of DMD cases are due to gene mutations, while around 70% of affected children have carrier mothers [2] Treatment Landscape - The current corticosteroid treatment rate in China has increased from 26.3% in 2015 to 54% in 2020, but nearly half of the patients have never used medication [6] - The lack of treatment is partly due to the absence of approved drugs, with Deflazacort only available through temporary importation [6][7] - Vamorolone, approved in December 2022, is expected to participate in national health insurance negotiations after passing the basic directory review [7] Gene Therapy Developments - Gene therapy is emerging as a significant area in DMD drug development, with various drugs approved globally, but only one gene therapy product has been approved [8][9] - Elevidys, a gene therapy drug, was approved by the FDA for DMD patients aged 4-5 years, but its high cost and associated controversies have raised concerns [9] - BBM-D101, a domestic gene therapy candidate, has received IND approval and is currently in clinical trials [9]